Republic of Korea-based biopharma company Celltrion is looking to accelerate its momentum in Europe; analysts belive that the company could receive the European Medicines Agency’s (EMA) approval to market its biosimilar of Roche’s blockbuster cancer treatment, Herceptin (trastuzumab), by March 2018.
Republic of Korea-based biopharma company Celltrion is looking to accelerate its momentum in Europe; according to The Investor, analysts believe that the company could receive the European Medicines Agency’s (EMA) approval to market its biosimilar of Roche’s blockbuster cancer treatment, Herceptin (trastuzumab), by March 2018.
Celltrion’s proposed trastuzumab biosimilar is the company’s third biosimilar product pursuing access to the European market, following the launch of Remsima, an infliximab biosimilar of Johnson & Johnson’s reference Remicade, and a rituximab biosimilar, Truxima, referenced on Rituxan.
“Herzuma will be well positioned for Celltrion to have confidence in sales based on 4 years of market experience (in Europe) and a strong partner network,” Park Si-hyeong, an analyst at IBK Securities, told The Investor.
Most recently, the FDA approved Mylan and Biocon's trastuzumab biosimilar, Ogivri. Other Herceptin products in development for the US and EU markets include:
In addition to its trastuzumab biosimilar, Celltrion is developing several other notable products:
The Investor reports that an official at Celltrion has indicated that Herzuma will be able to hit the European market 3 months after approval. Celltrion has not decided yet on its marketing partner for the drug, but it is likely to continue to work with existing partners such as Mundipharma, Biogaran, and Kern Pharma.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.